Pituitary apoplexy induced by gonadotropin-releasing hormone agonist administration: a rare complication of prostate cancer treatment.

2020 Adult C-reactive protein CT scan Cortisol Dexamethasone Diplopia GNRH Glucocorticoids Headache Hydrocortisone June Leuprolide acetate MRI Male Methylprednisolone Pituitary Pituitary adenoma Pituitary apoplexy Portugal Prolactin Prostate cancer Ptosis Radiotherapy Steroids TSH Testosterone Unusual effects of medical treatment Urology Vomiting White

Journal

Endocrinology, diabetes & metabolism case reports
ISSN: 2052-0573
Titre abrégé: Endocrinol Diabetes Metab Case Rep
Pays: England
ID NLM: 101618943

Informations de publication

Date de publication:
04 Jun 2020
Historique:
received: 08 04 2020
accepted: 06 05 2020
entrez: 20 6 2020
pubmed: 20 6 2020
medline: 20 6 2020
Statut: aheadofprint

Résumé

Gonadotropin-releasing hormone (GnRH) agonists, currently used in the treatment of advanced prostate cancer, have been described as a rare cause of pituitary apoplexy, a potentially life-threatening clinical condition. We report the case of a 69-year-old man with a known pituitary macroadenoma who was diagnosed with prostate cancer and started treatment with GnRH agonist leuprorelin (other hormones were not tested before treatment). Few minutes after drug administration, the patient presented with acute-onset severe headache, followed by left eye ptosis, diplopia and vomiting. Pituitary MRI revealed tumor enlargement and T1-hyperintense signal, compatible with recent bleeding sellar content. Laboratory endocrine workup was significant for low total testosterone. The patient was managed conservatively with high-dose steroids, and symptoms significantly improved. This case describes a rare phenomenon, pituitary apoplexy induced by GnRH agonist. We review the literature regarding this condition: the pathophysiological mechanism involved is not clearly established and several hypotheses have been proposed. Although uncommon, healthcare professionals and patients should be aware of this complication and recognize the signs, preventing a delay in diagnosis and treatment. Pituitary apoplexy (PA) is a potentially life-threatening complication that can be caused by gonadotropin-releasing hormone agonist (GnRHa) administration for the treatment of advanced prostate cancer. This complication is rare but should be taken into account when using GnRHa, particularly in the setting of a known pre-existing pituitary adenoma. PA presents with classic clinical signs and symptoms that should be promptly recognized. Patients should be instructed to seek medical care if suspicious symptoms occur. Healthcare professionals should be aware of this complication, enabling its early recognition, adequate treatment and favorable outcome.

Identifiants

pubmed: 32554827
doi: 10.1530/EDM-20-0018
pii: EDM200018
pmc: PMC7354737
doi:
pii:

Types de publication

Journal Article

Langues

eng

Références

Int Urol Nephrol. 2014 Sep;46(9):1775-8
pubmed: 24705727
Endocr Pract. 2007 Oct;13(6):642-6
pubmed: 17954421
J Clin Endocrinol Metab. 1995 Jul;80(7):2267-8
pubmed: 7608291
Int J Urol. 2011 Jan;18(1):83-4
pubmed: 21077963
Pituitary. 2006;9(3):263-5
pubmed: 16832587
World Neurosurg. 2016 Nov;95:616.e7-616.e9
pubmed: 27586180
J Endocrinol Invest. 1997 Oct;20(9):566-8
pubmed: 9413812
Lancet. 1995 Feb 18;345(8947):458
pubmed: 7853980
Endocrinol Diabetes Metab Case Rep. 2016;2016:160021
pubmed: 27284452
Int J Urol. 2006 Jan;13(1):87-8
pubmed: 16448441
Intern Med J. 2001 Jul;31(5):313-4
pubmed: 11512605
Endocrinol Nutr. 2015 Oct;62(8):411-2
pubmed: 26184059
BMJ Case Rep. 2017 Jul 14;2017:
pubmed: 28710301
Clin Endocrinol (Oxf). 1996 Jan;44(1):121-4
pubmed: 8706284
Cerebrovasc Dis. 2002;14(3-4):272
pubmed: 12403969
World J Surg Oncol. 2013 Oct 02;11:254
pubmed: 24088191
J Clin Neurosci. 2010 Sep;17(9):1201-3
pubmed: 20605467
J Clin Neurosci. 2015 Mar;22(3):601-3
pubmed: 25455737
Clin Endocrinol (Oxf). 2011 Jan;74(1):9-20
pubmed: 21044119
Ann Endocrinol (Paris). 2003 Jun;64(3):227-31
pubmed: 12910066
Neuro Endocrinol Lett. 2006 Oct;27(5):569-72
pubmed: 17159826
J Natl Compr Canc Netw. 2019 May 1;17(5):479-505
pubmed: 31085757
Pituitary. 2010;13(1):54-9
pubmed: 19842040

Auteurs

Mariana Barbosa (M)

Department of Endocrinology, Hospital de Braga, Braga, Portugal.

Sílvia Paredes (S)

Department of Endocrinology, Hospital de Braga, Braga, Portugal.

Maria João Machado (MJ)

Department of Neurosurgery, Hospital de Braga, Braga, Portugal.

Rui Almeida (R)

Department of Neurosurgery, Hospital de Braga, Braga, Portugal.
Pituitary Consult, Hospital de Braga, Braga, Portugal.

Olinda Marques (O)

Department of Endocrinology, Hospital de Braga, Braga, Portugal.
Pituitary Consult, Hospital de Braga, Braga, Portugal.

Classifications MeSH